Log in

NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

$2.83
-0.01 (-0.35 %)
(As of 02/17/2020 06:00 AM ET)
Add
Today's Range
$2.74
Now: $2.83
$2.87
50-Day Range
$2.53
MA: $3.04
$3.64
52-Week Range
$2.48
Now: $2.83
$12.15
Volume1.07 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:SPPI
CUSIP84763A10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees235
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.


Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company posted ($0.24) EPS. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

5 brokers have issued twelve-month price targets for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $21.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $13.20 in the next twelve months. This suggests a possible upside of 366.4% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

Press coverage about SPPI stock has trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Spectrum Pharmaceuticals.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 13,050,000 shares, an increase of 13.9% from the January 15th total of 11,460,000 shares. Based on an average daily volume of 2,311,200 shares, the days-to-cover ratio is currently 5.6 days. Currently, 13.3% of the company's shares are short sold. View Spectrum Pharmaceuticals' Current Options Chain.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Zynerba Pharmaceuticals (ZYNE), TG Therapeutics (TGTX), Verastem (VSTM), AT&T (T), Amicus Therapeutics (FOLD) and Novavax (NVAX).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), FMR LLC (1.23%), Bank of New York Mellon Corp (1.12%), ArrowMark Colorado Holdings LLC (0.95%) and Candriam Luxembourg S.C.A. (0.88%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., UBS Group AG and Arizona State Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Bank of New York Mellon Corp, Teza Capital Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $2.83.


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  444 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  787
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel